Duloxetine Hydrochloride Capsule, Delayed Release Pellets
Product Images NDC 50771-201

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 50771-201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Yaopharma Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (1566564938743)

Chemical structure of duloxetine hydrochloride, showing its molecular framework including a naphthalene group, a thiophene ring, and an amine hydrochloride group attached to the central carbon chain.*

FDA Label Image

20mg (20mg60)

Label for Duloxetine Delayed-Release Capsules, USP 20 mg by Yaopharma Co., Ltd. The label includes dosage and storage instructions, manufacturer details from Chongqing, China, and an image of yellow capsules. It states each capsule contains 20 mg of duloxetine hydrochloride equivalent. The package contains 60 capsules labeled Rx Only.*

FDA Label Image

30mg (30mg90)

Label for Duloxetine Delayed-Release Capsules, USP 30 mg by Yaopharma Co., Ltd. The label includes dosing instructions, storage conditions, manufacturer details, lot number, expiration date, and barcodes. It specifies the product contains 33.7 mg duloxetine hydrochloride equivalent to 30 mg duloxetine and that the package contains 90 capsules. The label shows a visual of a blue and yellow capsule and indicates the drug is Rx only.*

FDA Label Image

60mg (60mg30)

Label for Duloxetine Delayed-Release Capsules, USP 60 mg, oral capsule dosage form containing delayed release pellets. The label indicates a quantity of 30 capsules, manufactured by Yaopharma Co., Ltd. The label includes storage instructions, lot number, expiration date, and bar code. It also instructs pharmacists to dispense the enclosed medication guide to each patient.*

FDA Label Image

90beaf4a 3b90 2d90 E053 2995a90a335e

Label for Duloxetine Delayed-Release Capsules, USP, 20 mg strength, featuring a pink and white design. The label includes dispensing instructions, manufacturer details (Yaopharma Co., Ltd., Chongqing, China), and lot/expiration information. It states the capsule contains 22.4 mg duloxetine hydrochloride equivalent to 20 mg duloxetine, with a total count of 60 capsules. The label specifies 'Rx Only' and includes a barcode and a small image of the yellow capsules.*

FDA Label Image

90beaf4a 3b91 2d90 E053 2995a90a335e

Label for Duloxetine Delayed-Release Capsules, USP 30 mg manufactured by Yaopharma Co., Ltd. The label includes dosage form as capsules containing delayed-release pellets, a barcode, lot number, and expiration date (December 2016). It instructs pharmacists to dispense the enclosed medication guide and notes storage conditions and usage warnings.*

FDA Label Image

90bf2493 E18e 655e E053 2995a90ac94e

Label for Duloxetine Delayed-Release Capsules, USP 60 mg by Yaopharma Co., Ltd. The label includes drug name and strength, a blue and yellow capsule image, pharmacist instructions, storage and dosage warnings, manufacturing details from Chongqing, China, a barcode, lot number, and expiration date of 2018.12. The package contains 30 capsules.*

FDA Label Image

F1 (F1)

A Kaplan-Meier survival curve chart comparing relapse rates between placebo and duloxetine delayed-release capsules over time, showing the proportion of patients with relapse plotted against days from randomization up to 200 days. The chart displays two lines: a dashed line for placebo and a solid line for duloxetine delayed-release capsules.*

FDA Label Image

F2 (F2)

A line graph comparing the proportion of patients with relapse over time in days from randomization. It shows two treatments: placebo (dashed line) and duloxetine delayed-release capsules (solid line). The graph depicts lower relapse proportions over time for the duloxetine group compared to placebo.*

FDA Label Image

F3 (F3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine delayed-release capsules at 60 mg twice daily, 60 mg once daily, and 20 mg once daily, with a placebo group. The vertical axis represents the percentage of patients improved, and the horizontal axis shows the percent improvement in pain.*

FDA Label Image

F4 (F4)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine DR Capsules 60 mg BID, Duloxetine DR Capsules 60 mg QD, and placebo, showing patient improvement trends across different pain improvement percentages.*

FDA Label Image

F7 (F7)

A line chart comparing the percentage of patients improved against percent improvement in pain from baseline using last observation carried forward (BOCF). It shows data for Duloxetine delayed release (DR) capsules at doses of 60/120 mg once daily versus placebo. The vertical axis represents the percentage of patients improved, and the horizontal axis represents percent improvement in pain, ranging from above 0 to 100.*

FDA Label Image

F8 (F8)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo with Duloxetine DR Capsules 60 mg once daily, using diamond markers for duloxetine and cross markers for placebo. The graph illustrates greater patient improvement with duloxetine across the pain improvement spectrum.*

FDA Label Image

F9 (F9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine delayed-release capsules at 60/120 mg once daily. The graph shows two lines: one for placebo (marked with X) and one for Duloxetine (marked with diamonds), displaying trends of patient improvement across different pain improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.